Search

Your search keyword '"Pohlreich P"' showing total 189 results
Start Over Author "Pohlreich P"
189 results on '"Pohlreich P"'

2. Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

Author

Sureda, Anna, Chabannon, Christian, Masszi, Tamás, Pohlreich, David, Scheid, Christof, Thieblemont, Catherine, Wahlin, Björn E., Sakellari, Ioanna, Russell, Nigel, Janikova, Andrea, Dabrowska-Iwanicka, Anna, Touzeau, Cyrille, Esquirol, Albert, Jantunen, Esa, van der Werf, Steffie, Bosman, Paul, Boumendil, Ariane, Liu, Qianying, Celanovic, Marina, Montoto, Silvia, and Dreger, Peter

Published
2020
Full Text
View/download PDF

3. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Author

Morris, Curly, Chabannon, Christian, Masszi, Tamas, Russell, Nigel, Nahi, Hareth, Kobbe, Guido, Krejci, Marta, Auner, Holger W., Pohlreich, David, Hayden, Patrick, Basak, Grzegorz W., Lenhoff, Stig, Schaap, Nicolaas, van Biezen, Anja, Knol, Cora, Iacobelli, Simona, Liu, Qianying, Celanovic, Marina, Garderet, Laurent, and Kröger, Nicolaus

Published
2020
Full Text
View/download PDF

4. Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation

Author

Avivi, Irit, Boumendil, Ariane, Finel, Hervé, Nagler, Arnon, de Sousa, Aïda Botelho, Santasusana, Josep Maria Ribera, Vandenberghe, Elizabeth, Afanasyev, Boris, Bordessoule, Dominique, Moraleda, José Maria, Garcia, Eulogio Conde, Pohlreich, David, Garcia, Gonzalo Gutiérrez, Thomson, Kirsty, Or, Reuven, Beelen, Dietrich, Zuffa, Eliana, Giebel, Sebastian, Berthou, Christian, Salles, Gilles, Melpignano, Angela, Montoto, Silvia, and Dreger, Peter

Published
2018
Full Text
View/download PDF

5. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party

Author

Bento, L, Boumendil, A, Finel, H, Le Gouill, S, Amorim, S, Monjanel, H, Bouabdallah, R, Bay, J O, Nicolas-Virelizier, E, McQuaker, G, Rossi, G, Johnson, R, Huynh, A, Ceballos, P, Rambaldi, A, Bachy, E, Malladi, R, Orchard, K, Pohlreich, D, Tilly, H, Bonifazi, F, Poiré, X, Guilhot, F, Haenel, A, Crawley, C, Metzner, B, Gribben, J, Russell, N H, Damaj, G, Thomson, K, Dreger, P, and Montoto, S

Published
2017
Full Text
View/download PDF

6. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party

Author

Robinson, S P, Boumendil, A, Finel, H, Blaise, D, Poiré, X, Nicolas-Virelizier, E, Or, R, Malladi, R, Corby, A, Fornecker, L, Caballero, D, Pohlreich, D, Nagler, A, Thieblemont, C, Finke, J, Bachy, E, Vincent, L, Schroyens, W, Schouten, H, and Dreger, P

Published
2016
Full Text
View/download PDF

7. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT

Author

Robinson, S P, Canals, C, Luang, J J, Tilly, H, Crawley, C, Cahn, J Y, Pohlreich, D, Le Gouill, S, Gilleece, M, Milpied, N, Attal, M, Biron, P, Maury, S, Rambaldi, A, Maertens, J, Capria, S, Colombat, P, Montoto, S, and Sureda, A

Published
2013
Full Text
View/download PDF

22. [Prerequisites for preimplantation genetic diagnosis (PGD in carriers of mutations responsible for hereditary cancers]

Author

Hüttelová R, Kleibl Z, Rezátová J, Krutílková V, Foretová L, Novotný J, Kotlas J, Zikán M, and Pohlreich P

Subjects
Male, Heterozygote, Pregnancy, Neoplasms, Humans, Female, Genetic Predisposition to Disease, Fertilization in Vitro, Preimplantation Diagnosis
Abstract

Carriers of hereditary mutations in cancer susceptibility genes represent a limited but high-risk population characterized by a high probability of cancer development, frequently with its manifestation in early age and with a 50% chance of pathogenic allele inheritance by offspring. In case of monogenic disorders, preimplantation genetic diagnosis (PGD) could be used for characterization of the DNA region affected by pathogenic mutation in the early stages of an embryo created by in vitro fertilization (IVF). Therefore, the transfer of unaffected embryos could be performed based on the results of PGD genotyping, enabling the development of offspring not carrying the pathogenic alteration.Here we present the consensus of the collaborative group of the Society for Medical Genetics, the Czech Society for Oncology and other professionals for use of PGD in the Czech Republic for carriers of mutations in cancer susceptibility genes. We address the conditions, prerequisites, and limits of practical application of this method. We also point out specific issues of ovarian hyperstimulation in carriers of mutations in BRCA1, BRCA2, and p53, anticipating the increased risk of hormonally dependent breast and ovarian cancers development.We assume that a narrow but non-negligible subgroup of cancer susceptibility gene mutation carriers may benefit from PGD.They are mainly individuals deciding to undergo IVF and PGD recruited from mutation carriers with extreme concerns about transmitting the mutation to their children. The PGD in these individuals should be managed by a closely cooperating multidisciplinary team of professionals responsible for indication of PGD, giving complete information regarding the IVF and PGD procedures including their limits, evaluating individual risks and performing instrumental and laboratory procedures with respect to up-to-date good laboratory and clinical practice.

Published
2009

23. [Hereditary ovarian cancer]

Author

Zikán M, Foretová L, Cibula D, Kotlas J, and Pohlreich P

Subjects
Ovarian Neoplasms, Neoplastic Syndromes, Hereditary, Genes, BRCA2, Mutation, Genes, BRCA1, Humans, Breast Neoplasms, Female
Abstract

This article reviews the topic of hereditary ovarian cancer, describes persons at risk of hereditary disposition to cancer and gives instructions for genetic counselling and molecular analysis, including contacts to specialized centres in the Czech Republic.Review.Institute of Biochemistry and Experimental Oncology, Charles University in Prague.Hereditary ovarian cancer occurs in three autosomal dominant syndromes: appropriate hereditary ovarian cancer (HOC), hereditary breast and ovarian cancer (HBOC) and hereditary non-poliposis colorectal cancer (HNPCC). Physician in practice or specialist at the clinic should focus interest on patients form families with frequent occurrence of breast and/or ovarian cancer, patients with early onset disease or tumour duplicity (breast and ovarian cancer). Hereditary disposition to ovarian (and breast) cancer could be assessed by molecular genetic analysis of two main susceptibility genes BRCA1 and BRCA2, or other genes in families with diverse tumours. Molecular genetic analysis should be in any cases indicated by experienced clinical genetic. In the Czech Republic, the consensus of genetic and clinical care of risk patients was published and specialized centres for families with hereditary predisposition were settled in Prague and Brno.Persons with hereditary susceptibility to cancer constitute noted group where painstaking dispensarisation and preventive care may prevent malignancy or detect it in the early stage.

Published
2006

24. [Hereditary predisposition for the development of breast and ovarian carcinoma]

Author

Zikán M, Jancárková N, Pohlreich P, Matous B, Kleibl Z, Stríbrná J, and Zivný J

Subjects
Ovarian Neoplasms, Genetic Carrier Screening, Genes, BRCA2, Genes, BRCA1, Humans, Breast Neoplasms, Female, Genetic Predisposition to Disease
Abstract

Part of breast and ovarian cancer cases develops on the hereditary predisposition, i.e. mutation in one of predisposing genes. Although this proportion is relatively small, 5-10% of all breast and ovarian carcinomas, it represents a group with clearly defined etiologic factor. Predictive analysis of unaffected family members allows to identify individuals at high risk of cancer and to include them into the programme of primary and secondary cancer prevention. Following article presents basic review of the hereditary predisposition to breast and ovarian cancer focusing especially on BRCA1 and BRCA2 genes, which are responsible for almost three-quarters of those hereditary tumours.

Published
2004

29. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial

Author

Winston, Drew J, Mullane, Kathleen M, Cornely, Oliver A, Boeckh, Michael J, Brown, Janice Wes, Pergam, Steven A, Trociukas, Igoris, Žák, Pavel, Craig, Michael D, Papanicolaou, Genovefa A, Velez, Juan D, Panse, Jens, Hurtado, Kimberly, Fernsler, Doreen A, Stek, Jon E, Pang, Lei, Su, Shu-Chih, Zhao, Yanli, Chan, Ivan S F, Kaplan, Susan S, Parrino, Janie, Lee, Ingi, Popmihajlov, Zoran, Annunziato, Paula W, Arvin, Ann, Basso, AC, Bonvehi, P, Cerana, S, Dictar, MO, Campbell, P, Playford, G, Sasadeusz, J, Maertens, J, Poire, X, Sellesag, D, Schots, R, Theunissen, K, Willems, E, Alves, RS, Camargo, JFC, Castro, NS, Maria Fogliatto, L, Rodrigo, O, Courture, F, McGeer, A, Miller, M, Combariza, JF, Sossa, CL, Velez, JD, Nemet, D, Ostojic Kolonic, S, Jebavy, L, Mayer, J, Novak, J, Pohlreich, D, Maldonado, B, Gastinne, T, Karlin, L, Launay, O, Cornely, OA, Duerk, HA, Haenel, M, Heinz, W, Kaufmann, M, Panse, J, Teschner, D, Verbeek, M, Wulf, G, Aviv, F, Grisariu, S, Nagler, A, Yeshurun, M, Bosi, A, Corradini, P, Martinelli, G, Onida, F, Rambaldi, A, Velardi, A, Trociukas, I, Gomez, AD, Wondergem, MJ, Ypma, PF, Fanilla, E, Moreno Larrea, MDC, Abecasis, MM, Ferreira, RB, Geraldes, C, Castro, J, Afanasyev, BV, Kruchkova, IV, Zaritskiy, AY, Cheong, JW, Kim, SJ, Lee, DG, Yoon, SS, Aguado Bueno, B, Jarque Ramos, I, Solano Vercet, C, Cherif, H, Ljungman, P, Vaht, K, Cook, G, Kanfer, E, Milligan, DW, Parker, A, Akard, L, Bachier, C, Ball, ED, Betts, FR, Braunschweig, I, Brown, JM, Carroll, MP, Chandrasekar, PH, Collins, R, Cooper, B, Craig, M, D'Cunha, N, Donato, ML, Essell, J, Flomenberg, P, Freifeld, A, Freytes, C, Guarino, MJ, Hall, MC, Heimenz, JW, High, KP, Isola, LM, Kaminer, L, Klein, LM, Janakiraman, N, Kane, K, Komanduri, K, Krijanovski, OI, Lawrence, SJ, Leis, JF, Lill, M, Longo, WL, Lynch, JP, Mattar, BI, Mehta, J, Mullane, KM, Nathan, S, Papanicolaou, GA, Pergam, SA, Roy, V, Rybka, W, Safah, H, Saltzman, D, Segal, GM, Selby, GB, Schuster, MW, Shoham, S, Sloan, JM, Strasfeld, LM, Styler, M, Sullivan, K, Tse, W, Vance, EA, Winston, DJ, and Yanovich, S

Abstract

Recipients of autologous haemopoietic stem-cell transplants (auto-HSCT) have an increased risk of herpes zoster and herpes zoster-related complications. The aim of this study was to establish the efficacy and safety of an inactivated varicella zoster vaccine for the prevention of herpes zoster after auto-HSCT.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results